{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:39:14Z","timestamp":1787899154009,"version":"build-2784847793"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"DOI":"10.1186\/s12941-025-00795-7","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T12:01:13Z","timestamp":1744804873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence of antimalaria drug resistance-conferring mutations associated with sulphadoxine-pyrimethamineine-resistant Plasmodium falciparum in East Africa: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Wagaw","family":"Abebe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agenagnew","family":"Ashagre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadesse","family":"Misganaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelalem","family":"Dejazmach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getinet","family":"Kumie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye","family":"Nigatie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdu","family":"Jemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelalem","family":"Asmare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woldeteklehaymanot","family":"Kassahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Gedfie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermias","family":"Getachew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muluken","family":"Gashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisay","family":"Ayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalewayker","family":"Gashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assefa","family":"Sisay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selamyhun","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tegegne","family":"Eshetu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulat","family":"awoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birhanu","family":"Kassanew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atitegeb Abera","family":"Kidie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biruk Beletew","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melese Abate","family":"Reta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"795_CR1","first-page":"33","volume":"3","author":"O Olowe","year":"2015","unstructured":"Olowe O, et al. Malaria in Africa and the historical perspective: the journey so far. J Biol Med Sci. 2015;3:33\u201341.","journal-title":"J Biol Med Sci"},{"key":"795_CR2","doi-asserted-by":"crossref","unstructured":"Snow RW, Korenromp EL, Gouws E, Pediatric mortality in Africa: Plasmodium falciparum malaria as a cause or risk? The Intolerable Burden of Malaria II: What's New, What's Needed: Supplement to Volume 71 (2) of the American Journal of Tropical Medicine and Hygiene, 2004.","DOI":"10.4269\/ajtmh.2004.71.16"},{"key":"795_CR3","unstructured":"WHO, WHO Policy recommendation on Intermittent Preventive Treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa, March 2010. 2010, World Health Organisation."},{"key":"795_CR4","doi-asserted-by":"crossref","unstructured":"Mace KE, Malaria surveillance\u2014United States, 2017. MMWR. Surveillance Summaries, 2021. 70.","DOI":"10.15585\/mmwr.ss7002a1"},{"key":"795_CR5","volume-title":"World malaria report 2022","author":"WH Organization","year":"2022","unstructured":"Organization WH. World malaria report 2022. Geneva: World Health Organization; 2022."},{"key":"795_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-014-0254-7","volume":"13","author":"RW Snow","year":"2015","unstructured":"Snow RW. Global malaria eradication and the importance of Plasmodium falciparum epidemiology in Africa. BMC Med. 2015;13:1\u20133.","journal-title":"BMC Med"},{"key":"795_CR7","volume-title":"World malaria report 2019 (World Health Organization)","author":"WH Organization","year":"2018","unstructured":"Organization WH. World malaria report 2019 (World Health Organization). Geneva: World Health Organization; 2018."},{"issue":"1","key":"795_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/187152106774755590","volume":"5","author":"P Cravo","year":"2006","unstructured":"Cravo P, et al. Mechanisms of drug resistance in malaria: current and new challenges. Anti-Infect Agents Med Chem. 2006;5(1):63\u201373.","journal-title":"Anti-Infect Agents Med Chem"},{"issue":"7","key":"795_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025619","volume":"7","author":"D Menard","year":"2017","unstructured":"Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7(7): a025619.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"795_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/parasite\/2014059","volume":"21","author":"S Sinha","year":"2014","unstructured":"Sinha S, Medhi B, Sehgal R. Challenges of drug-resistant malaria. Parasite. 2014;21:61.","journal-title":"Parasite"},{"issue":"1","key":"795_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19026\/bjpt.6.5186","volume":"6","author":"M Eyasu","year":"2015","unstructured":"Eyasu M. Antimalarial drug resistance: in the past, current status and future perspectives. Br J Pharmacol Toxicol. 2015;6(1):1\u201315.","journal-title":"Br J Pharmacol Toxicol"},{"issue":"9326","key":"795_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0140-6736(02)09336-4","volume":"360","author":"JD Maguire","year":"2002","unstructured":"Maguire JD, et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet. 2002;360(9326):58\u201360.","journal-title":"Lancet"},{"issue":"7572","key":"795_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature15535","volume":"526","author":"S Bhatt","year":"2015","unstructured":"Bhatt S, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207\u201311.","journal-title":"Nature"},{"key":"795_CR14","doi-asserted-by":"crossref","unstructured":"Trape J-F, The public health impact of chloroquine resistance in Africa. The Intolerable Burden of Malaria: A New Look at the Numbers: Supplement to Volume 64 (1) of the American Journal of Tropical Medicine and Hygiene, 2001.","DOI":"10.4269\/ajtmh.2001.64.12"},{"issue":"9","key":"795_CR15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19(9):952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"795_CR16","volume-title":"World malaria day 2017: malaria prevention works, let\u2019s close the gap","author":"WH Organization","year":"2017","unstructured":"Organization WH. World malaria day 2017: malaria prevention works, let\u2019s close the gap. Geneva: World Health Organization; 2017."},{"issue":"25","key":"795_CR17","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.94.25.13944","volume":"94","author":"T Triglia","year":"1997","unstructured":"Triglia T, et al. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci. 1997;94(25):13944\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"795_CR18","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1371\/journal.pctr.0010014","volume":"1","author":"S Dunyo","year":"2006","unstructured":"Dunyo S, et al. Randomised trial of chloroquine\/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P falciparum. PLoS Clin Trials. 2006;1(3):e14.","journal-title":"PLoS Clin Trials"},{"issue":"5","key":"795_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-3156.2004.01239.x","volume":"9","author":"SG Staedke","year":"2004","unstructured":"Staedke SG, et al. Relationship between age, molecular markers, and response to sulphadoxine\u2013pyrimethamine treatment in Kampala. Uganda Trop Med Int Health. 2004;9(5):624\u20139.","journal-title":"Uganda Trop Med Int Health"},{"key":"795_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-10-245","volume":"10","author":"RA Mubjer","year":"2011","unstructured":"Mubjer RA, et al. Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications. Malar J. 2011;10:1\u20139.","journal-title":"Malar J"},{"key":"795_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-018-2185-9","volume":"17","author":"C Nsanzabana","year":"2018","unstructured":"Nsanzabana C, et al. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malar J. 2018;17:1\u201316.","journal-title":"Malar J"},{"key":"795_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-019-2986-5","volume":"18","author":"SA Diakit\u00e9","year":"2019","unstructured":"Diakit\u00e9 SA, et al. A comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in Mali. Malar J. 2019;18:1\u20139.","journal-title":"Malar J"},{"key":"795_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02655-16","author":"SM Chenet","year":"2017","unstructured":"Chenet SM, et al. Molecular profile of malaria drug resistance markers of Plasmodium falciparum in suriname. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.02655-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"795_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-015-0723-2","volume":"14","author":"A Heuchert","year":"2015","unstructured":"Heuchert A, et al. Molecular markers of anti-malarial drug resistance in southwest Ethiopia over time: regional surveillance from 2006 to 2013. Malar J. 2015;14:1\u20137.","journal-title":"Malar J"},{"key":"795_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijpddr.2020.11.006","volume":"15","author":"A Arya","year":"2021","unstructured":"Arya A, et al. Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: a systematic review of clinical studies from two malaria endemic regions\u2013India and sub-Saharan Africa. Int J Parasitol Drugs Drug Resist. 2021;15:43\u201356.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"795_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-11-1","volume":"11","author":"F Huang","year":"2012","unstructured":"Huang F, et al. Molecular epidemiology of drug resistance markers of Plasmodium falciparum in Yunnan province. China Malaria Journal. 2012;11:1\u20137.","journal-title":"China Malaria Journal"},{"issue":"3","key":"795_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14787210.2021.1962291","volume":"20","author":"C Rasmussen","year":"2022","unstructured":"Rasmussen C, Alonso P, Ringwald P. Current and emerging strategies to combat antimalarial resistance. Expert Rev Anti Infect Ther. 2022;20(3):353\u201372.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"795_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12936-022-04284-6","volume":"21","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, et al. Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya. Malar J. 2022;21(1):265.","journal-title":"Malar J"},{"key":"795_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1146\/annurev-micro-012220-064343","volume":"74","author":"F Rocamora","year":"2020","unstructured":"Rocamora F, Winzeler EA. Genomic approaches to drug resistance in malaria. Annu Rev Microbiol. 2020;74:761\u201386.","journal-title":"Annu Rev Microbiol"},{"issue":"3","key":"795_CR30","first-page":"147","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, et al. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. JBI Evid Implementation. 2015;13(3):147\u201353.","journal-title":"JBI Evid Implementation"},{"issue":"11","key":"795_CR31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"795_CR32","first-page":"14","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:14.","journal-title":"BMJ"},{"issue":"4","key":"795_CR33","first-page":"2","volume":"9","author":"G Kishoyian","year":"2019","unstructured":"Kishoyian G, et al. Molecular Monitoring of Plasmodium falciparum Resistance to Sulfadoxine-pyrimethamine in Western Kenya, 14 Years after its Withdrawal. Ann Med Health Sci Res. 2019;9(4):2.","journal-title":"Ann Med Health Sci Res"},{"issue":"1","key":"795_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3201\/eid2401.170864","volume":"24","author":"H Gupta","year":"2018","unstructured":"Gupta H, et al. Drug-resistant polymorphisms and copy numbers in Plasmodium falciparum, Mozambique, 2015. Emerg Infect Dis. 2018;24(1):40.","journal-title":"Emerg Infect Dis"},{"key":"795_CR35","unstructured":"Arnaldo P, et al., High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the emergence of sextuple mutant parasites during pregnancy in Mozambique. Evaluation of intermittent preventive treatment during pregnancy (IPTp) in Ch\u00f3kw\u00e8 district, Southern Mozambique: coverage and effect on pregnancy and parasitological outcomes, 2019: p. 137."},{"key":"795_CR36","unstructured":"Kateera F, et al., Molecular surveillance of chloroquine and sulphadoxine Pyrimethamine resistance markers reveals partial recovery of Chloroquine Susceptibility but sustained intense levels of Sulfadoxine-Pyrimethamine mutations at two sites of different malaria transmission intensities in Rwanda. Determinants of malaria control in a rural community in Eastern Rwanda: p. 50."},{"issue":"3","key":"795_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007223","volume":"13","author":"DW Juma","year":"2019","unstructured":"Juma DW, et al. The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis. PLoS Negl Trop Dis. 2019;13(3): e0007223.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"795_CR38","doi-asserted-by":"publisher","first-page":"e0005806","DOI":"10.1371\/journal.pntd.0005806","volume":"11","author":"E Lo","year":"2017","unstructured":"Lo E, et al. Transmission dynamics of co-endemic Plasmodium vivax and P falciparum in Ethiopia and prevalence of antimalarial resistant genotypes. PLoS Negl Trop Dis. 2017;11(7):e0005806.","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"795_CR39","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/infdis\/jix421","volume":"216","author":"MD Conrad","year":"2017","unstructured":"Conrad MD, et al. Impact of intermittent preventive treatment during pregnancy on Plasmodium falciparum drug resistance\u2013mediating polymorphisms in Uganda. J Infect Dis. 2017;216(8):1008\u201317.","journal-title":"J Infect Dis"},{"issue":"9","key":"795_CR40","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1128\/AAC.00507-15","volume":"59","author":"AK Mbonye","year":"2015","unstructured":"Mbonye AK, et al. Prevalence of Plasmodium falciparum resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda. Antimicrob Agents Chemother. 2015;59(9):5475\u201382.","journal-title":"Antimicrob Agents Chemother"},{"key":"795_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-015-0588-4","volume":"14","author":"M Shah","year":"2015","unstructured":"Shah M, et al. Assessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya. Malar J. 2015;14:1\u201314.","journal-title":"Malar J"},{"key":"795_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-015-0676-5","volume":"14","author":"MN Siame","year":"2015","unstructured":"Siame MN, et al. High prevalence of dhfr and dhps molecular markers in Plasmodium falciparum in pregnant women of Nchelenge district, Northern Zambia. Malar J. 2015;14:1\u20136.","journal-title":"Malar J"},{"key":"795_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-015-0977-8","volume":"14","author":"V Baraka","year":"2015","unstructured":"Baraka V, et al. High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Malar J. 2015;14:1\u20139.","journal-title":"Malar J"},{"key":"795_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-016-1387-2","volume":"15","author":"RA Kavishe","year":"2016","unstructured":"Kavishe RA, et al. Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine\u2013pyrimethamine in Tanzania. Malar J. 2016;15:1\u20138.","journal-title":"Malar J"},{"key":"795_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-019-3075-5","volume":"19","author":"SW Gikunju","year":"2020","unstructured":"Gikunju SW, et al. Prevalence of pfdhfr and pfdhps mutations in Plasmodium falciparum associated with drug resistance among pregnant women receiving IPTp-SP at Msambweni county referral hospital, Kwale county. Kenya Malar J. 2020;19:1\u20137.","journal-title":"Kenya Malar J"},{"key":"795_CR46","doi-asserted-by":"crossref","unstructured":"Molina-De la Fuente I et al., Seasonal malaria chemoprevention in a context of high presumed sulfadoxine-pyrimethamine resistance: malaria morbidity and molecular drug resistance profiles in South Sudan. Malar J. 2023; 22(1): 345.","DOI":"10.1186\/s12936-023-04740-x"},{"issue":"1","key":"795_CR47","doi-asserted-by":"publisher","first-page":"11416","DOI":"10.1038\/s41598-023-38481-3","volume":"13","author":"A Osborne","year":"2023","unstructured":"Osborne A, et al. Drug resistance profiling of asymptomatic and low-density Plasmodium falciparum malaria infections on Ngodhe island, Kenya, using custom dual-indexing next-generation sequencing. Sci Rep. 2023;13(1):11416.","journal-title":"Sci Rep"},{"key":"795_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-016-1287-5","volume":"15","author":"F Kateera","year":"2016","unstructured":"Kateera F, et al. Malaria case clinical profiles and Plasmodium falciparum parasite genetic diversity: a cross sectional survey at two sites of different malaria transmission intensities in Rwanda. Malar J. 2016;15:1\u201310.","journal-title":"Malar J"},{"key":"795_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-10-75","volume":"10","author":"S Ranjitkar","year":"2011","unstructured":"Ranjitkar S, et al. Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal. Malar J. 2011;10:1\u20138.","journal-title":"Malar J"},{"key":"795_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/aasopenres.12825.1","volume":"1","author":"J Abugri","year":"2018","unstructured":"Abugri J, et al. Prevalence of chloroquine and antifolate drug resistance alleles in Plasmodium falciparum clinical isolates from three areas in Ghana. AAS Open Res. 2018;1:1.","journal-title":"AAS Open Res"},{"key":"795_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-11-197","volume":"11","author":"N Wurtz","year":"2012","unstructured":"Wurtz N, et al. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malar J. 2012;11:1\u201310.","journal-title":"Malar J"},{"key":"795_CR52","first-page":"1","volume":"9","author":"H Quan","year":"2020","unstructured":"Quan H, et al. High multiple mutations of Plasmodium falciparum-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria. Infect Dis Pov. 2020;9:1\u201311.","journal-title":"Infect Dis Pov"},{"issue":"5","key":"795_CR53","doi-asserted-by":"publisher","first-page":"e02005","DOI":"10.1128\/spectrum.02005-22","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang X, et al. Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Central Africa between 2016 and 2021: wide geographic spread of highly mutated Pfdhfr and Pfdhps alleles. Microbiol Spectr. 2022;10(5):e02005-e2022.","journal-title":"Microbiol Spectr"},{"key":"795_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.644576","volume":"11","author":"D Zhao","year":"2021","unstructured":"Zhao D, et al. Surveillance of antimalarial drug-resistance genes in imported Plasmodium falciparum isolates from Nigeria in Henan, China, 2012\u20132019. Front Cell Infect Microbiol. 2021;11: 644576.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"795_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107071","volume":"63","author":"A Sinha","year":"2024","unstructured":"Sinha A, et al. Meta-analysis on Plasmodium falciparum sulfadoxine-pyrimethamine resistance-conferring mutations in India identifies hot spots for genetic surveillance. Int J Antimicrob Agents. 2024;63(3): 107071.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"795_CR56","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12936-022-04403-3","volume":"21","author":"R Rana","year":"2022","unstructured":"Rana R, et al. Molecular surveillance of anti-malarial drug resistance genes in Plasmodium falciparum isolates in Odisha, India. Malar J. 2022;21(1):394.","journal-title":"Malar J"},{"issue":"1","key":"795_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12936-022-04059-z","volume":"21","author":"A Mahamar","year":"2022","unstructured":"Mahamar A, et al. Effect of three years\u2019 seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali. Malar J. 2022;21(1):39.","journal-title":"Malar J"},{"issue":"3","key":"795_CR58","first-page":"171","volume":"4","author":"BK Abuaku","year":"2004","unstructured":"Abuaku BK, Koram KA, Binka FN. Antimalarial drug use among caregivers in Ghana. Afr Health Sci. 2004;4(3):171\u20137.","journal-title":"Afr Health Sci"},{"issue":"5","key":"795_CR59","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3201\/eid2605.190556","volume":"26","author":"E Rogier","year":"2020","unstructured":"Rogier E, et al. Nationwide monitoring for Plasmodium falciparum drug-resistance alleles to chloroquine, sulfadoxine, and pyrimethamine, Haiti, 2016\u20132017. Emerg Infect Dis. 2020;26(5):902.","journal-title":"Emerg Infect Dis"},{"key":"795_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-020-03543-8","volume":"20","author":"PTN Niba","year":"2021","unstructured":"Niba PTN, et al. Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998\u20132020). Malar J. 2021;20:1\u201320.","journal-title":"Malar J"},{"issue":"8","key":"795_CR61","doi-asserted-by":"publisher","first-page":"e0256343","DOI":"10.1371\/journal.pone.0256343","volume":"16","author":"AGB Tuedom","year":"2021","unstructured":"Tuedom AGB, et al. Antimalarial drug resistance in the Central and Adamawa regions of Cameroon: Prevalence of mutations in P. falciparum crt, Pfmdr1, Pfdhfr and Pfdhps genes. PLoS ONE. 2021;16(8):e0256343.","journal-title":"PLoS ONE"},{"key":"795_CR62","doi-asserted-by":"crossref","unstructured":"Mohamed NS, et al., Historical literature review and molecular analysis of malaria drug resistance markers of Plasmodium falciparum field-isolates from Sudan. 2020.","DOI":"10.21203\/rs.2.24565\/v1"},{"key":"795_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-12-107","volume":"12","author":"B Fall","year":"2013","unstructured":"Fall B, et al. Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J. 2013;12:1\u201311.","journal-title":"Malar J"},{"issue":"10","key":"795_CR64","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1046\/j.1365-3156.2000.00632.x","volume":"5","author":"S Biswas","year":"2000","unstructured":"Biswas S, et al. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. Tropical Med Int Health. 2000;5(10):737\u201343.","journal-title":"Tropical Med Int Health"},{"issue":"10","key":"795_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165515","volume":"11","author":"NA Norahmad","year":"2016","unstructured":"Norahmad NA, et al. Prevalence of Plasmodium falciparum molecular markers of antimalarial drug resistance in a residual malaria focus area in Sabah, Malaysia. PLoS ONE. 2016;11(10): e0165515.","journal-title":"PLoS ONE"},{"key":"795_CR66","doi-asserted-by":"publisher","first-page":"1167220","DOI":"10.3389\/fcimb.2023.1167220","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang S, et al. A review of malaria molecular markers for drug resistance in Plasmodium falciparum and Plasmodium vivax in China. Front Cell Infect Microbiol. 2023;13:1167220.","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"795_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/tropicalmed7080155","volume":"7","author":"I Issa","year":"2022","unstructured":"Issa I, et al. Prevalence of mutations in the Pfdhfr, Pfdhps, and Pfmdr1 genes of malarial parasites isolated from symptomatic patients in Dogondoutchi, Niger. Trop Med Infect Dis. 2022;7(8):155.","journal-title":"Trop Med Infect Dis"},{"key":"795_CR68","doi-asserted-by":"publisher","DOI":"10.1017\/9781108575041","volume-title":"African development, African transformation: how institutions shape development strategy","author":"L Sign\u00e9","year":"2018","unstructured":"Sign\u00e9 L. African development, African transformation: how institutions shape development strategy. Cambridge: Cambridge University Press; 2018."},{"key":"795_CR69","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ijid.2021.04.081","volume":"107","author":"M L\u2019Episcopia","year":"2021","unstructured":"L\u2019Episcopia M, et al. Targeted deep amplicon sequencing of antimalarial resistance markers in Plasmodium falciparum isolates from Cameroon. Int J Infect Dis. 2021;107:234\u201341.","journal-title":"Int J Infect Dis"},{"key":"795_CR70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.actatropica.2018.06.016","volume":"185","author":"SJ Smith","year":"2018","unstructured":"Smith SJ, et al. Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone. Acta Trop. 2018;185:363\u201370.","journal-title":"Acta Trop"},{"issue":"10","key":"795_CR71","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/j.1365-3156.2007.01904.x","volume":"12","author":"M Ndounga","year":"2007","unstructured":"Ndounga M, et al. Therapeutic efficacy of sulfadoxine\u2013pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville. Congo Trop Med Int Health. 2007;12(10):1164\u201371.","journal-title":"Congo Trop Med Int Health"},{"issue":"12","key":"795_CR72","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1017\/S0031182011000746","volume":"138","author":"I Naidoo","year":"2011","unstructured":"Naidoo I, Roper C. Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology. 2011;138(12):1469\u201379.","journal-title":"Parasitology"},{"issue":"10","key":"795_CR73","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.pt.2013.08.002","volume":"29","author":"I Naidoo","year":"2013","unstructured":"Naidoo I, Roper C. Mapping \u2018partially resistant\u2019, \u2018fully resistant\u2019, and \u2018super resistant\u2019malaria. Trends Parasitol. 2013;29(10):505\u201315.","journal-title":"Trends Parasitol"},{"key":"795_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-13-152","volume":"13","author":"SI Matondo","year":"2014","unstructured":"Matondo SI, et al. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania. Malar J. 2014;13:1\u20137.","journal-title":"Malar J"},{"issue":"9","key":"795_CR75","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/genes10090692","volume":"10","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, et al. Genetic variations associated with drug resistance markers in asymptomatic Plasmodium falciparum infections in Myanmar. Genes. 2019;10(9):692.","journal-title":"Genes"},{"issue":"1","key":"795_CR76","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12936-023-04651-x","volume":"22","author":"LP Kojom Foko","year":"2023","unstructured":"Kojom Foko LP, et al. Nationwide spatiotemporal drug resistance genetic profiling from over three decades in Indian Plasmodium falciparum and Plasmodium vivax isolates. Malar J. 2023;22(1):236.","journal-title":"Malar J"},{"issue":"7","key":"795_CR77","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ijpara.2020.12.011","volume":"51","author":"R Chaturvedi","year":"2021","unstructured":"Chaturvedi R, et al. Geographical spread and structural basis of sulfadoxine-pyrimethamine drug-resistant malaria parasites. Int J Parasitol. 2021;51(7):505\u201325.","journal-title":"Int J Parasitol"},{"issue":"1","key":"795_CR78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/nyas.12662","volume":"1342","author":"A Heinberg","year":"2015","unstructured":"Heinberg A, Kirkman L. The molecular basis of antifolate resistance in Plasmodium falciparum: looking beyond point mutations. Ann N Y Acad Sci. 2015;1342(1):10\u20138.","journal-title":"Ann N Y Acad Sci"},{"key":"795_CR79","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02093-20","author":"C Cal\u00e7ada","year":"2020","unstructured":"Cal\u00e7ada C, et al. Expansion of a specific Plasmodium falciparum PfMDR1 haplotype in Southeast Asia with increased substrate transport. MBio. 2020. https:\/\/doi.org\/10.1128\/mbio.02093-20.","journal-title":"MBio"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-025-00795-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:03:26Z","timestamp":1744815806000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-025-00795-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1186\/s12941-025-00795-7","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}